key: cord-0935455-qewlj142
authors: Gary, Ebony N.; Warner, Bryce M.; Parzych, Elizabeth M.; Griffin, Bryan D.; Zhu, Xizhou; Tailor, Nikesh; Tursi, Nicholas J.; Chan, Mable; Purwar, Mansi; Vendramelli, Robert; Choi, Jihae; Frost, Kathy L.; Reeder, Sophia; Liaw, Kevin; Tello, Edgar; Ali, Ali R.; Yun, Kun; Pei, Yanlong; Thomas, Sylvia P.; Rghei, Amira D.; Guilleman, Matthew M.; Muthumani, Kar; Smith, Trevor; Wootton, Sarah K.; Patel, Ami; Weiner, David B.; Kobasa, Darwyn
title: A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogens
date: 2021-06-08
journal: iScience
DOI: 10.1016/j.isci.2021.102699
sha: 2321775a7e6e667fc4f41d27c95de364ba877b42
doc_id: 935455
cord_uid: qewlj142

More than 100 million people have been infected with SARS-CoV-2. Common laboratory mice are not susceptible to wild-type SARS-CoV-2 infection, challenging the development and testing of effective interventions. Here, we describe the development and testing of a mouse model for SARS-CoV-2 infection based on transduction of the respiratory tract of laboratory mice with an adeno-associated virus vector (AAV6.2FF) expressing human ACE-2 (AAV6.2FF-hACE2). We validated this model using a previously described synthetic DNA vaccine plasmid, INO-4800 (pS). Intranasal instillation of AAV6.2FF-hACE2 resulted in robust hACE2 expression in the respiratory tract. pS induced robust cellular and humoral responses. Vaccinated animals were challenged with 105 TCID50 SARS-CoV-2 (hCoV-19/Canada/ON-VIDO-01/2020) and euthanized four days post-challenge to assess viral load. One immunization resulted in 50% protection and two immunizations were completely protective. Overall, the AAV6.2FF-hACE2 mouse transduction model represents an easily accessible, genetically diverse mouse model for wild-type SARS-CoV-2 infection and preclinical evaluation of potential interventions.

More than 100 million people have been infected with SARS-CoV-2. Common laboratory mice are not 27 susceptible to wild-type SARS-CoV-2 infection, challenging the development and testing of effective 28

interventions. Here, we describe the development and testing of a mouse model for SARS-CoV-2 infection 29 based on transduction of the respiratory tract of laboratory mice with an adeno-associated virus vector 30 (AAV6.2FF) expressing human ACE-2 (AAV6.2FF-hACE2). We validated this model using a previously 31 In December 2019 a novel coronavirus was identified as the etiological agent of a severe-acute respiratory 52 syndrome (SARS)-like disease in Wuhan China . The previously unknown 53 betacoronavirus, now identified as SARS-CoV-2, causes 2019 coronavirus disease (COVID-19) and has 54 well as serum antibodies following a single immunization. We observed a dose-dependent increase in GC T FH 134 when the dose was increased from 3.5ug to 10ug, however no significant increase was observed when 135 increasing from 2.5ug to 25ug (Fig. 3A, C) . This was also true for the frequencies of GC B cells (Fig. 3B, D ) . 136

In keeping with this pattern, we observed significantly increased RBD-specific IgG in the serum of animals 137 immunized with 10ug of pS but not those immunized with 25ug of pS (Fig. 3E) . These data indicate that the 138 10ug dose of pS which induces robust cellular immunity as measured by ICS and ELISpot also engenders 139 strong germinal center responses including induction of T FH and GC B cells. Sera from immunized animals was 140 collected at the time of euthanasia and assayed for SARS-CoV-2 receptor binding domain (RBD) specific 141 antibody. We detected significant increases in SARS-CoV-2 RBD-specific IgG endpoint titers in the sera of 142 immunized mice at day 7 post-2 nd immunization ( Fig. 4A) . Upon isotype characterization we noted increased 143 endpoint titers of RBD-binding IgG of all isotypes ( Fig. 4B-D) , of which IgG2a was the most prominent, with a 144 greater than 50-fold increase in the ratio of IgG2a to IgG1 (Fig. 4E) , suggestive of strongly T H 1-biased 145 immunity. In these experiments, anti-RBD antibody titers remained increased in the serum of pS immunized 146 mice for greater than 80 days post final immunization (Fig. 4F) . These data suggest the pS induces robust 147 humoral responses in mice. 148

In order to interrogate the functional impact of these DNA vaccine-induced SARS-CoV-2 binding 149 antibodies, we performed in vitro pseudovirus neutralization assays in which SARS-CoV-2 spike pseudotyped 150 lentiviruses were preincubated with sera from immunized animals prior to infection of huACE2-expressing CHO 151 cells. Sera from pS-immunized mice was capable of potently inhibiting pseudoviral infectivity (Fig. 4G) and 152 displayed reciprocal ID 50 titers that were statistically significantly increased compared to naïve mouse sera 153 (Fig. 4H) . Taken together these data strongly indicate that pS DNA antigens are immunogenic in vivo, resulting 154 in robust anti-spike humoral immunity, which is T H 1 biased, persistent, and capable of neutralizing SARS-CoV-155 2 pseudoviruses in vitro. infectivity in vitro (Fig. 5C) . Four days post-infection, mice were euthanized, and SARS-CoV-2 viral RNA and 164 live viral titers were measured in the lung via RT-qPCR and TCID50 assay. Animals which received two doses 165 of pS had significantly decreased SARS-CoV-2 lung viral titers (Fig. 5D) and RNA (Fig. 5E ) in their lungs. 166

Strikingly, a single immunization lowered viral loads in 90% of animals, and 50% of animals which received a 167 single immunization displayed TCID50 values at or below the lower limit of detection in their lungs at the time 168 of euthanasia (Fig. 5D) . Furthermore, all immunized animals had statistically significant decreases in viral RNA 169

in the lung at this timepoint (Fig. 5E) . We observed strong inverse correlations between serum IgG endpoint 170 titers and lung TCID50 values and viral RNA loads (Fig. 5F, H) . A similar inverse correlation was observed 171 between neutralization titer and TCID50 and viral RNA loads post-challenge (Fig. 5G, I) . These data support a 172 significant role for anti-SARS-CoV-2 humoral immunity in mediating protection in vivo. 173

Previous studies on vaccines targeting SARS-CoV-1 and MERS-CoV suggest that inclusion of the 174 nucleocapsid antigen is not protective and may promote vaccine-mediated disease enhancement in challenge 175 models. Immune responses to the nucleocapsid of SARS-CoV-2 have not been studied in great detail. 176

However, recent evidence suggests that functional antibody responses directed against the nucleocapsid can 177 distinguish convalescent patients from patients who succumb to COVID-19 (Atyeo et al., 2020). We designed a 178 DNA vaccine encoding the SARS-CoV-2 nucleocapsid protein (pN) and immunized animals once with 10ug of 179 this antigen alone or in combination with 10ug of pS (pS+pN). Immunized animals were transduced with 180 AAV6.2FF.hACE2 followed by challenge and viral load was measured in lungs using TCID50 assay. As 181 expected animals immunized with pN alone were unable to neutralize spike-pseudotyped viruses whole sera 182 from animals immunized with pS alone or co-immunized with pS and pN was equally capable of neutralizing 183 SARS-CoV-2 spike pseudotyped viruses in vitro (Supp. Fig. 1A ). Following challenge, co-immunization with 184 pN did not significantly change the outcome of pS-mediated protection as measured by TCID50 (Supp. Fig.  185 1B). These data suggest that nucleoprotein-directed responses alone following a single immunization were not 186 sufficient for protection in this model. 187

This data supports the further study of the AAV6.2FF-hACE2 transduction model as an easily 188 accessible small-animal model for wild-type SARS-CoV-2 infection, which may be of value in preclinical immune-therapeutics. 191

We used an AAV6.2FF-hACE2-transduction model to generate long-term expression of human ACE2 for providing care to the animals used in these studies and for additional financial support. We would also like 247 to thank the flow cytometry core facility at the Wistar Institute. This work was supported by NIH NCI award T32 248 CA09171 (ENG) and NIH NIAID award T32-AI-055400 (EMP) with additional support from CEPI/Inovio 249 Pharmaceuticals. Graphical abstract created in BioRender. Use Committee. Submandibular bleeds were taken weekly to isolate sera for future assays. Blood via cardiac 341 puncture, spleens, and Bronchoalveolar lavage (BAL) fluid were collected at the time of euthanasia. 342

Pseudovirus neutralization assay. SARS-CoV-2 pseudovirus were produced using HEK293T cells transfected 343 with 1:1 ratio of IgE-SARS-CoV-2 S plasmid (Genscript) and pNL4-3.Luc.R-E-plasmid (NIH AIDS 344 reagent)using Gene jammer (Agilent) as transfection reagent. Forty-eight hours post transfection, transfection 345 supernatant was collected, enriched with FBS to 12% final volume, and stored at -80°C. SARS-Cov-2 346 pseudovirus neutralization assay was set up using D10 media (DMEM supplemented with 10%FBS and 1X 347

Penicillin-Streptomycin) in a 96 well format using huCHOAce2 cells (Creative Biolabs, Catalog No. VCeL-348 Wyb019). For neutralization assay, 10,000 CHO-ACE2 cells were plated in 96-well plates and rested overnight 349 at 37˚C and 5% CO2 for 24 hours. Following day, sera from INO-4800 vaccinated and control groups were 350 heat inactivated and serially diluted as desired. Sera were incubated with a fixed amount of SARS-Cov-2 351 pseudovirus for 90 minutes at RT following which the mix was added to huCHOAce2 cells and allowed to 352 incubate in a standard incubator (37% humidity, 5% CO2) for 72h. Post 72h, cells were lysed using britelite 353 plus luminescence reporter gene assay system (Perkin Elmer Catalog no. 6066769) and RLU were measured 354

Distinct early serological signatures track with SARS-CoV-2 survival

Universal real-time PCR for the detection and quantification of adeno-448 associated virus serotype 2-derived inverted terminal repeat sequences

Antibody-based protection against 450 HIV infection by vectored immunoprophylaxis

Antibody-based protection against 452 HIV infection by vectored immunoprophylaxis

The 457 pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

DNA 459 vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune 460 responses in mice

CD40-targeted S1 subunit vaccine protects against MERS-CoV and S1-associated pulmonary 463 immunopathology in transgenic human DPP4 mouse model

A SARS-CoV-2 infection model in mice demonstrates protection by 466 neutralizing antibodies

Clinical features of 468 patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

Syrian hamsters as a small animal model for SARS-CoV-2 infection and 471 countermeasure development

Effects of Toll-like receptor stimulation on eosinophilic infiltration 474 in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus 475 vaccine

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-478 19) with gastrointestinal symptoms

A lung tropic AAV vector improves survival in a mouse model of 482 surfactant B deficiency

A lung tropic AAV vector improves survival in a mouse model of surfactant 485 B deficiency

IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Safety and immunogenicity of an anti-Middle East respiratory 490 syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

A synthetic consensus anti-spike protein DNA vaccine induces 495 protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates

498 AAV vector distribution in the mouse respiratory tract following four different methods of administration

AAV vector distribution in the mouse respiratory tract following four different methods of 502 administration

AAV 504 vector distribution in the mouse respiratory tract following four different methods of administration

Immunogenicity of a DNA vaccine candidate for COVID-19

Immunogenicity of a DNA vaccine candidate for COVID-19

Generation 512 of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment

Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on 515 challenge with the SARS virus

A novel triple-mutant AAV6 capsid induces rapid 518 and potent transgene expression in the muscle and respiratory tract of mice

AAV-Mediated Gene Delivery to the Lung

A Novel Triple-Mutant AAV6 Capsid Induces Rapid and Potent Transgene 523 Expression in the Muscle and Respiratory Tract of Mice

Antibody-dependent SARS coronavirus infection is mediated by 526 antibodies against spike proteins

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation 529 and impaired function

Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus 532 infection

A DNA 534 vaccine induces SARS coronavirus neutralization and protective immunity in mice

A 536 pneumonia outbreak associated with a new coronavirus of probable bat origin

A novel 538 coronavirus from patients with pneumonia in China

Potently neutralizing and protective human antibodies against SARS-CoV-2

as the reciprocal serum dilution at which RLU were reduced by 50% compared to RLU in virus control wells 356 after subtraction of background RLU in cell control wells. Scientific) were coated with 1µg/mL RBD of SARS-CoV-2 spike protein (Genscript) in PBS overnight at 4°C. 403The following day, plates were washed with PBS-0.5% Tween 20 and blocked with PBS-10% fetal bovine 404 serum. Next, the plates were again washed and subsequently incubated with diluted mouse sera for two hours. 405Following primary serum incubation, plates were incubated with goat anti-mouse IgG-HRP (Bethyl) for one 406 hour at room temperature. TMB (Thermo) was used to develop the binding signal. Upon stopping with 1N 407 sulfuric acid, plates were read with the BioTek Synergy 2 plate reader (BioTek) at 450nm. Data were 408 subsequently exported to Microsoft Excel and analyzed in graphpad prism version 8.Statistical analysis. All statistics were analyzed using GraphPad Prism 8. Error bars represent means ± SEM or 411 the mean± SD where denoted. Normality was determined using the Shapiro-Wilk normality test. Outliers were 412 determined and removed using the ROUT algorithm. For data deemed normal, ordinary one-way analysis of 413 variance (ANOVA) was performed to determine statistical significance between groups of three or more 414 (Tukey's multiple comparison test). For data deemed non-normal, a non-parametric Kruskal-Wallis test was 415 performed in order to determine statistical differences between groups of three or more. Statistical differences 416 between groups of two were determined via unpaired t test for data deemed normal, or Mann-Whitney U test 417 for data deemed non-normal. In all data *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001.